Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries

Peuskens, Joseph; Olivares, J.M.; Pecenak, Jan; Tůma, Ivan; Weg, Haye bij de; Eriksson, Lars; Resseler, S; Akhras, Kasem; Jacobs, An

doi:10.1185/03007990903488670

Cited by 58 publications

(53 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other benefits include more consistent bioavailability [Remington and Adams, 1995] and more predictable correlation between dosage and plasma levels [Rocca et al 2013], reduced peaktrough plasma levels [McEvoy, 2006], improved patient outcomes [Peuskens et al 2010a;Kaplan et al 2013], improved patient and physician satisfaction [Peuskens et al 2010b], lower relapse rates [Emsley et al 2008a[Emsley et al , 2008bGaebel et al 2010] than oral therapy and more regular contact with the mental healthcare team [Pandarakalam, 2003].…”

Section: Disadvantagesmentioning

confidence: 99%

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Brissos¹,

Ruiz‐Veguilla

Taylor

et al. 2014

Therapeutic Advances in Psychopharmacology

232

200

View full text Add to dashboard Cite

Historical background of long-acting injectable antipsychotics Soon after the introduction of antipsychotics (APs) in the 1950s, poor adherence to oral formulations was found to be a critical issue. This led to the development in 1966 of the first long-acting injectable (LAI) AP fluphenazine enanthate, and fluphenazine decanoate some 18 months later, to reduce the incidence of side effects of the former [Johnson, 2009]. Haloperidol decanoate became available in Europe in 1981 and in the USA in 1986 [Knudsen, 1985]. Clinical trial results showed a dramatic reduction in the morbidity of schizophrenia [Gottfries and Green, 1974; Johnson, 2009]. However, the concept of LAIs for schizophrenia was not initially received warmly by the medical profession for fears of increased side effects, lack of efficacy, and the fact this was seen as an attempt by psychiatrists to impose a treatment upon patients without due regard to their feelings or rights [Johnson, 2009] as well as the potential for medicolegal problems [Glazer and Kane, 1992]. However, with subsequent surveys and trials suggesting their benefits [Rifkin et al. 1977; Schooler et al. 1980; Hogarty et al. 1979], LAIs became more widely adopted. The introduction of the oral second-generation APs (SGAs) brought claims of better tolerance and less severe side effects, even though their use may be hindered by metabolic syndrome [Meyer and Stahl, 2009]. They also have potential to prevent or reverse accelerated frontotemporal cortical grey matter decline, and to provide a greater degree of neuroprotection than first generation APs (FGAs) [Keefe et al. 2004; Robinson et al. 2006]. The introduction of SGAs led to a decline in the use of LAI FGAs [Patel et al. 2003; Patel and David, 2005]. However, it soon became clear that atypical characteristics did not bring better adherence rates with oral SGAs. The recent introduction of LAI SGAs allows psychiatrists once

show abstract

Section: Disadvantagesmentioning

confidence: 99%

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Brissos¹,

Ruiz‐Veguilla

Taylor

et al. 2014

Therapeutic Advances in Psychopharmacology

232

200

View full text Add to dashboard Cite

show abstract

“…La RILP es un tratamiento que, además de ser eficaz en el manejo de los síntomas de la enfermedad, permite una adecuada adherencia al tratamiento por parte de los pacientes, lo que disminuye el número de hospitalizaciones y tiempo de estancia intrahospitalaria. 5,19,23,27,31,37,[51][52][53] Una de las principales implicaciones de estos resultados se encuentra dirigida a las concepciones en torno al uso de antipsicóticos inyectables como tratamiento de primera elección para la esquizofrenia, incluso en situaciones clínicas no relacionadas con dificultades en la adherencia al tratamiento. Con el uso de la RILP, los pacientes se verían beneficiados por un antipsicótico eficaz para el tratamiento de los síntomas, el cual no tiene que ser tomado diariamente, lo que aumenta las probabilidades de una adecuada adherencia y reduce las posibilidades de una recaída y eventual hospitalización.…”

Section: Discussionunclassified

“…27,29,30 Debido a esto, se ha propuesto llevar a cabo estudios observacionales, con adecuados diseños metodológicos, encaminados a valorar la eficacia de tales medicamentos en la práctica clínica cotidiana. El Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia (e-STAR) 31 es un registro internacional de tipo observacional del uso de la risperidona inyectable de liberación prolongada (RILP) en la práctica clínica cotidiana en un periodo de seguimiento a 24 meses. Adicionalmente, se registra la información un año previo al inicio de la RILP.…”

Section: Introductionunclassified

Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento

Apiquian¹,

Córdoba²,

Louzã³

et al. 2013

Salud Ment

View full text Add to dashboard Cite

SUMMARYSchizophrenia is a chronic psychiatric disorder associated to high healthcare costs mainly driven by inpatient care. Lack of adherence to antipsychotic treatment is a common reason for relapse and rehospitalization leading to poor prognosis and global functional impairment of patients. Risperidone long-acting injection (RLAI) has demonstrated its efficacy in treating symptoms of schizophrenia and offers the potential to improve adherence to treatment. ObjectiveTo determine clinical and functional efficacy of RLAI and use of health resources (eg., hospitalizations) in a 2-year follow up study among patients with schizophrenia from Latin America. MethodThe electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an observational study of patients who start treatment with RLAI. Data from patients recruited in Mexico, Colombia and Brazil were collected retrospectively for one year prior to baseline, at baseline and every three months for 24 months. Hospitalization rates and treatment regime were registered. Efficacy was assessed using the Clinical Global Impression of Illness-Severity Scale (CGI-S), while the Global Assessment of Functioning (GAF) and the Personal and Social Performance (PSP) were used for the evaluation of functioning. ResultsSeventy-three patients completed the two-year follow-up. The proportion of patients hospitalized declined from 16.4% before treatment to 4.1% after 2 years of treatment with RLAI. Only 2.7% discontinued the treatment due to lack of efficacy. Significant improvements were reported in illness severity as well as in global functioning assessed by the CGI-S, GAF and PSP scales, respectively. DiscussionOur results give further support of the efficacy of RLAI for the treatment of schizophrenia. Additional to symptom severity reduction and functional recovery, improved treatment adherence and reduced hospitalization rates were observed with the use of RLAI. In a real world clinical setting, RLAI offer an effective long-term treatment for patients with schizophrenia, with a lower use of healthcare resources.Key words: Risperidone long-acting injection, schizophrenia, Latin America, treatment adherence. RESUMENLa esquizofrenia genera elevados costos al sistema de salud. La falta de adherencia al tratamiento es una de las principales causas de recaídas y hospitalizaciones en la esquizofrenia. Lo anterior conduce a un pobre pronóstico y deterioro funcional de los pacientes. La risperidona inyectable de liberación prolongada (RILP) ha demostrado su eficacia en el tratamiento de la esquizofrenia, ofreciendo la posibilidad de que los pacientes tengan una mayor adherencia terapéutica. ObjetivoDeterminar la eficacia y efecto sobre la funcionalidad y el uso de recursos hospitalarios de la RILP en una muestra de pacientes con esquizofrenia de América Latina a dos años de seguimiento. MétodoEl Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR) es un estudio observacional del uso de la RILP en la esquizofrenia. Se reclutaron pacientes de M...

show abstract

“…Positive results were found in an international postmarketing observational trial with long-acting injectable risperidone, eSTAR (electronic Schizophrenia Treatment Adherence Registry) (33). Summary of twoyear results from six countries based on data from 1659 patients showed a high persistence with depot risperidone, up to 85% (33).…”

Section: Long-acting Injectable Antipsychotics (Depot Formulations)mentioning

confidence: 93%

“…Summary of twoyear results from six countries based on data from 1659 patients showed a high persistence with depot risperidone, up to 85% (33).…”

Section: Long-acting Injectable Antipsychotics (Depot Formulations)mentioning

confidence: 99%

Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update

Mohr¹,

Volavka²

2012

Dusunen Adam

View full text Add to dashboard Cite

Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries

Abstract: These observational data confirm that RLAI is an effective treatment in schizophrenia and high levels of adherence to therapy offers an opportunity for effective long-term disease management and significant sustained decreases in hospitalization.

Cited by 58 publications

References 22 publications

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento

Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update

Contact Info

Product

Resources

About